Details for Patent: 9,006,430
✉ Email this page to a colleague
Which drugs does patent 9,006,430 protect, and when does it expire?
Patent 9,006,430 protects TRUQAP and is included in one NDA.
This patent has twenty-two patent family members in seventeen countries.
Summary for Patent: 9,006,430
Title: | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
Abstract: | The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR; J-Jis N═C(R), (R)C═N, (R)N—C(O), (R)C—C(O), N═N or (R)C═C(R); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Qis a bond or a saturated Chydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRor NRCO where Ris hydrogen or methyl, or Ris a Calkylene chain linked to R or a carbon atom of Qto form a cyclic moiety; and wherein the carbon atoms of the linker group Qmay optionally bear one or more substituents selected from fluorine and hydroxy; Qis a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Qis other than a bond; G is hydrogen, NRR, OH or SH provided that when E is aryl or heteroaryl and Qis a bond, then G is hydrogen; Ris hydrogen or an aryl or heteroaryl group, with the proviso that when Ris hydrogen and G is NRR, then Q is a bond; and R, R, R, Rand Rare as defined in the claims. |
Inventor(s): | Berdini Valerio, Boyle Robert George, Saxty Gordon, Walker David Winter, Woodhead Steven John, Wyatt Paul Graham, Donald Alastair, Caldwell John, Collins Ian, Da Fonseca Tatiana Faria |
Assignee: | |
Application Number: | US14310475 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,006,430
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,006,430
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 051342 | ⤷ Try a Trial | |||
Argentina | 103370 | ⤷ Try a Trial | |||
Austria | E513549 | ⤷ Try a Trial | |||
Cyprus | 1115946 | ⤷ Try a Trial | |||
Denmark | 2272517 | ⤷ Try a Trial | |||
European Patent Office | 1812004 | ⤷ Try a Trial | |||
European Patent Office | 2272517 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |